Influence of SLCO1B3 genetic polymorphisms on the incidence of adverse effects and trough plasma con

来源 :第十二届国际胃癌学术会议 | 被引量 : 0次 | 上传用户:hnzxjl
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Background: Imatinib(Marketed as Glivec in USA and Gleevec in Europe)is a tyrosine kinase inhibitor(TKI),commonly used as a first-line therapy for treatment of Gastrointestinal Stromal Tumors(GIST)and Chronic Myeloid Leukemia(CML).
其他文献
Background: As per GLOBOCAN 2012 Gastric cancer is one of the most common cancers worldwide.It is also one of the most common causes for cancer related mortality.The prognosis remains poor for this ca